Research Article

Never-in-Mitosis A-Related Kinase 8 (NEK8) Regulates Adipogenesis, Glucose Homeostasis, and Obesity

Yan-Jun Wang, Ying Zhao, Yun-Wei Sun, and Yan Chen

Department of Endocrinology, The Second Hospital of Jilin University, Changchun 130041, China

Correspondence should be addressed to Yan Chen; cheny99@jlu.edu.cn

Received 2 August 2022; Revised 11 November 2022; Accepted 16 November 2022; Published 30 November 2022

Academic Editor: Valentina Pallottini

Copyright © 2022 Yan-Jun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Adipogenesis is a complex biological process and the leading main cause of obesity. We evaluated the role of never-in-mitosis A-related kinase 8 (NEK8) in adipocyte development and insulin sensitivity in the present study.

Methods. NEK8 expression was manipulated using a specific shRNA or the NEK8-full-length expressing recombinant plasmids. The interaction between NEK8 and Tafazzin (TAZ, an oncogenic transcriptional regulator) was examined by Co-immunoprecipitation (Co-IP) and confocal immunofluorescence staining. Western blot assay was performed to determine the protein expression. The in vivo role of NEK8 was explored in a mouse model of high-fat diet-(HFD-) induced insulin resistance.

Results. During adipogenesis, the expression of NEK8 was elevated while TAZ was downregulated. Overexpression of NEK8 promoted lipid accumulation and expression of markers for adipocyte differentiation. Mechanically, NEK8 interacted with TAZ and suppressed its expression in adipocytes. Functionally, lentiviral-mediated NEK8 inhibition ameliorates HFD-induced insulin resistance in adipocytes.

Conclusion. These findings suggest that NEK8 plays a critical role in adipocyte proliferation, providing novel insight into the link between NEK8 and type 2 diabetes- (T2DM-) related obesity.

1. Background

Type 2 diabetes (T2DM) has reached epidemic proportions and is the ninth major cause of death. T2DM is a complex, multifactorial disorder driven by genetic and environmental risk factors. Moreover, T2DM is a major risk factor for developing cardiovascular diseases [1–3]. Numerous studies have proven that adipose tissue is a subtle endocrine organ and plays an essential role in energy homeostasis. The abnormal function of adipocytes is closely related to lipid deposition, increased adipose tissue mass, and insulin resistance [4, 5]. Therefore, investigating the underlying mechanisms of adipogenesis may shed light on therapeutic strategies against T2DM.

Never-in-mitosis A-related kinase 8 (NEK8), also called NPHP9, is a member of the serine/threonine-protein kinase family and plays a critical role in cell cycle progression, primary cilia disassembly, and DNA damage response [6]. In addition, RNA interference-mediated NEK8 knockout delayed gastric cancer cell proliferation, colony formation, and migration by interacting with von-Hippel-Lindau tumor suppressor protein (pVHL) [7]. It has been proposed that NPHP-associated disease mechanisms are achieved by regulating Wnt, Sonic hedgehog, and Hippo pathways [8, 9]. A previous study reported that NEK8 leads to nuclear translocation and activation of Tafazzin (TAZ, an oncogenic transcriptional regulator), thereby accelerating TAZ-mediated tumorigenesis [10]. In addition, TAZ was found to associate and to regulate obesity, and studies showed that mice that are knockdown of TAZ are protected from diet-induced obesity [11, 12]. Meanwhile, loss of NEK8 leads to abnormal organ development, and this effect was dependent on the activation of the Hippo pathway member TAZ [13]. However, the expression pattern and functional relevance of NEK8 and TAZ in adipogenesis remain unknown.

In the present study, we first investigated the functional role of NEK8 in adipocyte function and its association with TAZ using an in vivo model of HFD-induced type 2 diabetes...
in C57/BL6 mice. This research would be helpful for understanding the mechanisms of NEK8 in type 2 diabetes (T2DM)-related obesity.

2. Materials and Methods

2.1. Cell Culture. 3T3-L1 cells and HEK293T cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA). Cells were maintained in a humidified incubator with 5% CO₂ at 37°C. For standard induction of adipocyte differentiation, the confluent 3T3-L1 cells were incubated with the differentiation media (plus 0.5 mM isobutylmethyl xanthine, 1 μM dexamethasone, and 10 μg/mL insulin) for 48 hours. The differentiation pattern was studied both by observing the morphological changes and by estimating oil droplet accumulation in the cells. The differentiated adipocytes in culture after 4–10 days were taken for oil red O staining and to evaluate its ability to glucose uptake.

2.2. Transfections. Transfections of plasmid DNA or shRNA were performed using the Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer’s instructions. The NEK8 overexpression was conducted by constructing the full-length NEK8 sequences into cells via pEX-2 plasmids (GenePharma, Shanghai, China). The pLKO lentiviral shRNA specific sequences into cells via pEX-2 plasmids (GenePharma, Shanghai, China). The pLKO lentiviral shRNA specific for NEK8 was obtained from Addgene (Cambridge, MA, USA), and a negative control (NC) shRNA was obtained from Genechem (Shanghai, P.R. China).

2.3. Quantitative Real-Time PCR (qRT-PCR). Total RNAs were isolated from cells using Trizol Reagent (Invitrogen, USA) and reversed transcribed into cDNA using QuantiTect Reverse Transcription Kit (Qiagen). The relative expression of genes was measured by qRT-PCR. The assay was performed using SYBR Premix Ex Taq™ (Takara, Otsu, Japan) on an Applied Biosystems 7500 Real Time machine (Applied Biosystems, Foster City, CA, USA) and reversely transcribed into cDNA using QuantiTect reverse transcription kit (Takara, Otsu, Japan). The following primers used were obtained from Genechem (Shanghai, P.R. China).

2.4. Western Blot. Total protein lysates were extracted from cells transfected with shRNA and overexpression plasmid. Briefly, the cells were washed with PBS, lysed with a mammalian lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 0.4 mM phenylmethylsulfonyl fluoride (PMSF)) and sonicated, then denatured by incubation for 5 min at 95°C in a sample buffer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% β-mercaptoethanol, and 0.01% bromophenol blue). After that, the samples were subjected to 4–20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for fractionation and then transferred to polyvinylidene difluoride (PVDF) membranes and were blocked in skimmed milk at room temperature for 1 h. Membranes were incubated with the primary antibodies (including anti-NEK8, TAZ, Pref-1, Adiponectin, PPARγ, FABP4, and PEPCK antibodies overnight at 4°C. After being washed three times with PBST buffer, the membranes were incubated with secondary antibodies conjugated with horseradish peroxidase for 1 h at room temperature. Protein bands were detected by enhanced chemiluminescence (ECL) method. Antibodies were used, including rabbit anti-NEK8 antibody (1:1000, Abcepta), rabbit anti-TAZ antibody (1:1000, Abcam), mouse anti-Pref-1 antibody (1:500, Bio-Technne), mouse anti-Adiponectin antibody (1:1000, Abcam), rabbit anti-PPARγ antibody (1:2000, cell signaling), rabbit anti-FABP4 antibody (1:1000, Abcam), and rabbit anti-PEPCK antibody (1:1000, Sigma). Secondary antibodies included HRP-conjugated goat anti-rabbit IgG antibody and anti-mouse IgG antibody (1:2000, Jackson).

2.5. Immunoprecipitation. 3T3-L1 cells were transiently transfected with the NEK8 overexpression plasmid with 0, 0.5, 1, and 2 μg, and then incubated for an additional 48 hours. Then, 3T3-L1 cells were collected and lysed in RIPA lysis buffer (Yeasen, Shanghai) supplemented with protease inhibitor cocktail (Yeasen) for 30 min at 4°C, centrifuged at 8, 800 rpm for 10 min, and the supernatant was collected and divided into three 1.5 ml tubes (one for input, one for IgG, and one for IP). Immunoprecipitation was conducted using antibodies against NEK8 or TAZ. Briefly, 1 μg primary antibody against NEK8 or TAZ was added to 200 μL cell lysates and incubated with rotation at 4°C for 2 h. Rabbit immunoglobulin G (IgG) was used as a negative control. Subsequently, proteins were precipitated with agarose A/G (Santa Cruz) and washed 5-6 times with RIPA lysis buffer. Immunoprecipitates and input were subjected to run SDS-PAGE, the next step same as western blot assay.

2.6. Immunofluorescence. The expression of NEK8 and TAZ were measured through immunofluorescent staining method. Briefly, cells were fixed for 15 minutes with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with blocking buffer, and incubated with indicated primary and secondary antibodies. Finally, the nuclei of the cells were stained and mounted with DAPI-Fluor mount reagent. All images were observed by a Nikon A1 microscope (Nikon, Japan).

2.7. Insulin-Stimulated 2-Deoxyglucose Uptake. 3T3-L1 cells were incubated in FBS- and glucose-free DMEM at 37°C for 2 h and subsequently stimulated with 10 μg/mL insulin for 30 min. Then, the glucose uptake and lactate product were measured using the Glucose Uptake Assay Kit (ab136955) from Abcam (Shanghai, China) according to the manufacturer’s instructions.

2.8. Animals and Groups. The study protocol was approved by the Animal Care and Ethics Committee of College of Veterinary Medicine of Jilin University (Changchun, China). A total of 24 male C57BL/6 mice (age, 6 to 8 weeks; weight, 32–36 g) were purchased from Shanghai SLAC Laboratory.
Animal Co., Ltd. (Shanghai, China). Mice were housed with a 12 h light-dark cycle at 23 ± 2 °C and 70% humidity, with free access to water and food. Mice were randomly divided into 4 groups, and each group contains six animals and was kept on normal chow or HFD. We observed that after 4 weeks of HFD feeding, the mice will produce a significant increase in body weight, basal/fasting plasma glucose, insulin, basal triglyceride, and total cholesterol levels. Thus, the mice were injected with lentiviruses carrying NEK8 shRNA through the tail vein after 4 weeks of HFD feeding. Body weight was measured weekly. The epididymal white adipose tissue (eWAT) was collected immediately after mice sacrificed at 6 weeks, frozen in liquid nitrogen, and stored at -80°C for later analysis.

2.9. Metabolic Experiments. Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (ITT) were performed to examine the metabolic manifestation. For IPGTT, glucose at 2 g/kg was intraperitoneally administered, and blood glucose was measured at 0, 15, 30, 60, 90, and 120 min. For ITT, insulin at 0.75 IU/kg was intraperitoneally injected, and blood glucose was measured at 0, 15, 30, 60, 90, and 120 min.

2.10. Statistical Analysis. Experimental data were presented as mean ± standard deviation (SD) and analyzed using SPSS 20.0 software (IBM, Almond, NY, USA). Student’s t-test was used for comparison between two groups. For more than two groups, mean values were compared using one-way ANOVA followed by the Dunnett’s posttest. Values of P < 0.05 were considered statistically significant.

3. Results

3.1. NEK8 Was Gradually Upregulated during Adipocyte Differentiation in 3T3-L1 Cells. Representative images of differentiating 3T3-L1 adipocytes were observed by optical microscopic observation and visualized by oil red O staining. The mRNA levels of NEK8 and TAZ were examined by real time PCR, and the protein levels of NEK8, TAZ, adiponectin, Pref-1, and PPARγ were examined by western blot. β-Actin was used as a loading control. The data are represented as mean values ± SD from three independent experiments in triplicate, *P < 0.05, and **P < 0.01.
Figure 2: NEK8 physically associated with TAZ. (a) 3T3-L1 cells were transiently transfected with the NEK8 overexpression plasmid with 0, 0.5, 1, and 2 μg and then incubated for an additional 48 hours, and the cell lysates were collected to determine the NEK8 and TAZ level by western blot assay and β-actin as a loading control. (b, c) Co-immunoprecipitation (Co-IP) was conducted to detect the interaction between NEK8 and TAZ, and IgG was used as a control. (d) Confocal immunofluorescence staining was used to detect the colocalization of NEK8 and TAZ.

Figure 3: NEK8 promotes the adipogenesis in 3T3-L1 cells. 3T3-L1 cells were transiently transfected with the NEK8 shRNA and overexpression plasmids and then incubated for 4 days. (a) The protein levels of NEK8, TAZ, adiponectin, Pref-1, PPARγ, FABP4, and PEPCK were examined by western blot and β-actin as a loading control. (b) Representative images of differentiating 3T3-L1 adipocytes after oil red O staining. (c, d) The insulin-stimulated glucose uptake was determined in 3T3-L1 cells under NEK8 silenced or overexpressed. The data are represented as mean values ± SD from three independent experiments in triplicate, *P < 0.05, and **P < 0.01.
western blot assay was performed to detect the protein expression level of NEK8, TAZ, as shown in Figure 1(d). Our western blot data confirmed that protein expression variation of NEK8 and TAZ paralleled mRNA levels during adipogenesis in 3T3-L1 cells (Figure 1(d)). Further, the adiponectin and PPAR were increased, and Pref-1 was decreased during adipogenesis in 3T3-L1 cells (Figure 1(d)).

3.2. NEK8 Physically Associated with TAZ. In addition, we evaluated the effects of TAZ on the expression of NEK8. Western blot assay showed that NEK8 overexpression represses TAZ in a dose-dependent manner in 3T3-L1 cells (Figure 2(a)). Collectively, these data suggested that NEK8 and TAZ are involved during adipogenesis. Given that NEK8 serves as a regulator of TAZ, we performed Co-immunoprecipitation (Co-IP) assays to explore whether NEK8 can interact with TAZ. We immunoprecipitated the proteins by using an anti-NEK8 (Figure 2(b)) and anti- TAZ (Figure 2(c)) antibody in 3T3-L1 cells. Co-IP assays showed that TAZ was detected in the samples immunoprecipitated by the anti-NEK8 antibody but not in those immunoprecipitated by IgG (Figure 2(b)), while the NEK8 was detected in the samples immunoprecipitated by the anti- TAZ antibody (Figure 2(c)). Furthermore, we explored whether NEK8 and TAZ are colocalized by confocal immunofluorescence microscopy. Consequently, both NEK8 and TAZ were localized in the cytoplasm in 3T3-L1 and HEK293T cells. The merged images revealed the clear colocalization of the two proteins (Figure 2(d)). These results confirm the specific interaction of NEK8 and TAZ.

3.3. NEK8 Promotes Adipogenesis in 3T3-L1 Cells. To unequivocally prove an effect of NEK8 on adipogenesis, the markers of terminally differentiated adipocytes [15](which enhance 3T3-L1 fibroblast proliferation and accelerate adipocyte differentiation) and undifferentiated preadipocytes [16](which is highly expressed in 3T3-L1 cells but is extinguished during adipocyte differentiation) were determined by western blot, as shown in Figure 3(a), and the adiponectin and PPARγ were increased, and TAZ and Pref-1 were decreased in NEK8-overexpressed 3T3-L1 cells. In contrast, the adiponectin and PPARγ were decreased, and TAZ and Pref-1 were increased in NEK8-silenced 3T3-L1 cells. Moreover, our data revealed that knockdown of NEK8 significantly suppressed the accumulation of intracellular lipids, as evidenced by oil red O staining, while overexpression of
NEK8 enhanced the lipid deposition (Figure 3(b)). Furthermore, we assessed the effects of NEK8 on the expression of markers for adipocyte differentiation. Western blot assay showed that the protein expression levels of PPARy and the target genes FABP4 and PEPCK were significantly decreased following NEK8 silencing, while overexpression of NEK8 significantly promoted these proteins expression (Figure 3(a)). In addition, insulin-stimulated glucose uptake was sensitized in 3T3-L1 adipocytes transfected with NEK8, whereas knockdown of NEK8 led to glucose tolerance (Figures 3(c) and 3(d)). These results suggest that NEK8 acts as a regulator of adipocyte differentiation and function.

3.4. Inhibition of NEK8 Improved Insulin Sensitivity in HFD-Fed Mice. We further explored the functional significance of NEK8 using HFD-fed mice. The body weight of mice injected with shNEK8 was obviously decreased compared to HFD mice and shNC + HFD mice (P < 0.001) (Figure 4(a)). To further evaluate the effect of NEK8 inhibition on insulin sensitivity, IPGTT and ITT assays were performed in this research. As shown, NEK8-silenced HFD mice have the lowest glucose levels during IPGTT and ITT compared to HFD and shNC + HFD mice (P < 0.001). Moreover, we found the increased expression of NEK8, and PPARy in the epididymal white adipose tissue was significantly decreased in NEK8-inhibited HFD mice (Figure 4(d)). These in vivo data confirmed that NEK8 affects glucose homeostasis under pathological conditions.

4. Discussion

The NIMA-related kinase (NEK) family of serine/threonine kinases is critical regulators of cell proliferation, primary cilia disassembly, and DNA damage response [17], and one family member is NEK8, which has a broad tissue distribution and was initially discovered in a juvenile cystic kidney mouse [14, 18]. NEK8 is a critical component of the DNA damage response that links replication stress with cystic kidney disorders [19]. Additionally, NEK8 has been identified as a tumor-associated gene that promotes cancer cell proliferation, colony formation, and migration [20].

In the present study, we explored the regulatory role of NEK8 in 3T3-L1 adipocyte differentiation and the underlying mechanism. We observed a significant elevation of NEK8 during adipogenesis (Figure 1). Functionally, knockdown of NEK8 significantly suppressed lipid accumulation and adipogenic gene expressions, such as PPARy, FABP4, and PEPCK (Figure 3(a)), leading to inhibition lipid deposition (Figure 3(b)). Moreover, silencing of NEK8 also inhibited insulin-stimulated glucose uptake in vitro (Figures 3(c) and 3(d)), which supported in vivo experiments. Collectively, these results suggest that NEK8 acts as a regulator of adipocyte differentiation and function.

Furthermore, we identified that TAZ was physically associated with NEK8 (Figure 2), and TAZ is a negative regulator of PPARy activity in adipocytes [21]. Based on these findings, there was no doubt that NEK8 possesses a positive regulatory on adipocyte differentiation by interacting and transcriptionally repressing TAZ, thereby regulating glucose homeostasis and insulin sensitivity.

The Hippo pathway is an important hub coordinating cell proliferation and differentiation to regulate tissue growth [22]. TAZ, also called WWTR1, is a critical effector of this pathway and regulates cell proliferation, survival, and differentiation. A large amount of evidence has confirmed the functional relevance of TAZ during adipogenesis [23, 24]. A previous study demonstrated that TAZ suppression increased the lipid deposits and adipogenic gene expression in 3T3-L1 cells [25]. Recently, knockdown of TAZ has been reported to improve glucose tolerance and insulin sensitivity in obese mice [21]. Our data showed that overexpression of NEK8 significantly suppressed TAZ expression in the present study (Figure 2(a)). Moreover, the interaction of NEK8 and TAZ was measured by Co-IP and confocal immunofluorescence approach, and our data demonstrate NEK8 is physically associated with TAZ (Figures 2(b)–2(d)), indicating that NEK8 interacted with TAZ to regulate adipocyte differentiation and functions. Nevertheless, the precise mechanism by which NEK8 regulates TAZ and its downstream pathway needs further investigation.

The in vivo research of NEK8 knockdown was performed in HFD-fed mice, as shown in Figure 4, and the bodyweight of mice injected with shNEK8 was decreased compared to HFD mice and shNC + HFD mice. In addition, we evaluated the effect of NEK8 inhibition on insulin sensitivity, and our data showed NEK8-inhibited HFD mice have the lowest glucose levels during IPGTT and ITT (Figures 4(a)–4(c)).

In conclusion, our study identified that NEK8 is physically associated with TAZ and promotes adipocyte differentiation. These findings provide a novel insight into the link between NEK8 and metabolic disorders.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

There is no conflict of interest to disclose.

Authors’ Contributions

YC conceived and designed the experiments; YJW performed the experiments; YZ analyzed the data; YWS and YC wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Chinese Postdoctoral Science Foundation (No. 2019M651218) and the Natural Science Foundation of Jilin Province of China (No. 20190201031JC).
References

[1] J. S. Skyler, G. L. Bakris, E. Bonifacio et al., “Differentiation of diabetes by pathophysiology, natural history, and prognosis,” Diabetes, vol. 66, no. 2, pp. 241–255, 2017.

[2] H. Kolb and S. Martin, “Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes,” BMC Medicine, vol. 15, no. 1, p. 131, 2017.

[3] P. Zimmet, K. G. Alberti, and J. Shaw, "Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001.

[4] S. N. Saxton, B. J. Clark, S. B. Withers, E. C. Eringga, and A. M. Heagerty, “Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue,” Physiological Reviews, vol. 99, no. 4, pp. 1701–1763, 2019.

[5] K. G. Stenkula and C. Erlanson-Albertsson, "Adipose cell size: importance in health and disease,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 315, no. 2, pp. R284–R295, 2018.

[6] L. Moniz, P. Dutt, N. Haider, and V. Stambolic, “NEK family of kinases in cell cycle, checkpoint control and cancer,” Cell Division, vol. 6, no. 1, 2011.

[7] X. F. Ding, J. Chen, J. Zhou, G. Chen, and Y. L. Wu, “Never-in-mitosis A-related kinase 8, a novel target of von-Hippel-Lindau tumor suppressor protein, promotes gastric cancer cell proliferation,” Oncology Letters, vol. 16, no. 5, pp. 5900–5906, 2018.

[8] M. T. F. Wolf and F. Hildebrandt, “Nephronophthisis,” Pediatric Nephrology, vol. 26, no. 2, pp. 181–194, 2011.

[9] S. Habbig, M. P. Bartram, R. U. Müller et al., “NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway,” Journal of Cell Biology, vol. 193, no. 4, pp. 633–642, 2011.

[10] S. Habbig, M. P. Bartram, J. G. Sägmüller et al., “The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ,” Human Molecular Genetics, vol. 21, no. 26, pp. 5528–5538, 2012.

[11] L. K. Cole, E. M. Mejia, M. Vandel et al., “Impaired cardioliop biosynthesis prevents hepatic steatosis and diet-induced obesity,” Diabetes, vol. 65, no. 11, pp. 3289–3300, 2016.

[12] L. K. Cole, P. Agarwal, C. A. Doucette et al., “Tafazzin deficiency reduces basal insulin secretion and mitochondrial function in pancreatic islets from male mice,” Endocrinology, vol. 162, no. 7, 2021.

[13] V. Frank, S. Habbig, M. P. Bartram et al., “Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression,” Human Molecular Genetics, vol. 22, no. 11, pp. 2177–2185, 2013.

[14] H. J. Choi, J. R. Lin, J. B. Vannier et al., “NEK8 Links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies,” Molecular Cell, vol. 51, no. 4, pp. 423–439, 2013.

[15] Y. Fu, N. Luo, R. L. Klein, and W. T. Garvey, “Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation,” Journal of lipid research, vol. 46, no. 7, pp. 1369–1379, 2005.

[16] Y. Wang, K.-A. Kim, J.-H. Kim, and H. S. Sul, “Pref-1, a predipocyte secreted factor that inhibits adipogenesis,” The Journal of Nutrition, vol. 136, no. 12, pp. 2953–2956, 2015.

[17] A. Peres de Oliveira, L. Kazuo Issayama, I. C. Betim Pavan et al., “Checking NEKs: overcoming a bottleneck in human diseases,” Molecules, vol. 25, no. 8, p. 1778, 2020.